MetalloBio’s compounds are active against a broad spectrum of bacterial pathogens; notably, both Gram-negative and Gram-positive clinical isolates, including the so-called ESKAPE pathogens designated by the World Health Organisation (WHO) as being a major risk to human health.
Fig: Efficacy In Vitro — Minimum Inhibitory and Bactericidal Concentration µM – MIC comparison with standard antibiotics
The compounds display novel bactericidal modes of action, are capable of penetrating and disrupting biofilms, show no antagonism to other antibiotic compounds tested, and appear to elicit little to no genetic resistance. Wild type strains are as susceptible to MetalloBio compounds as their drug resistant pathogenic counterparts strongly supporting the notion that MetalloBio’s compounds kill bacteria by way of previously unknown mechanisms.
These bacterial species are responsible for a range of complicated infections; that is, infections which are mediated by multiple bacterial pathogens simultaneously. The properties of MetalloBio’s compounds are thus likely to be well-suited to tackling infections such as complicated urinary tract infections (cUTIs) or hospital-acquired pneumonia and ventilator-associated pneumonia (HAP and VAP, respectively).
